Atara Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (ATRA) on November 1, 2023. The report discloses the entry into a new sales agreement to facilitate the potential sale of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of an "at-the-market" (ATM) offering facility with an aggregate offering price of up to $100.0 million.
Material Changes
- New ATM Facility: Entered into a sales agreement with Cowen and Company, LLC ("TD Cowen") to sell shares of common stock up to $100.0 million.
- Commission Structure: The Company will pay TD Cowen a commission of up to 3.0% of gross sales proceeds.
- Termination of Prior Agreement: Upon the effectiveness of the new registration statement, the existing sales agreement dated November 26, 2021, with TD Cowen will terminate.
Outlook, Risks, and Management Commentary
The Company is not obligated to make any sales under the new facility. Sales will be made at the Company's sole discretion based on market conditions. The offering will terminate upon the sale of all shares subject to the facility or earlier termination in accordance with its terms. No securities may be sold until the related Form S-3 registration statement becomes effective.
Key Facts for Investor Verification
- Verify the effectiveness date of the Form S-3 registration statement required to activate the $100.0 million ATM facility.
- Monitor future filings for actual sales volumes and proceeds generated under the new agreement.
- Confirm the termination of the November 2021 sales agreement once the new registration is effective.
- Review the Company's cash position in subsequent quarterly reports to assess the necessity of utilizing this facility.